



RECEIVED

NOV 06 2002

Replace ment page

TECH CENTER 1600/2900

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995: No persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/049,502
		Filing Date	February 15, 2002
		First Named Inventor	Said M. Sebti
		Group Art Unit	1646 1636
		Examiner Name	(not yet assigned) M. Maruch
		Attorney Docket Number	USF-T144X

Sheet	2	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mm	R1	CHEN, Z. et al., Farnesylated and Geranylgeranylated RhoB Suppress the Transformation of PANC-1 Human Pancreatic Cancer Cells; Proceedings of the 91 st Annual Meeting of the American Association for Cancer Research, Volume 14, page 220, abstract no. 1402. (2002)	
mm	R2	DU, W. et al., Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB, Molecular and Cellular Biology, Volume 19, number 3, March 1999, pages 1831-1840.g	(
mm	R3	CHEN, Z. et al., Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice, Journal of Biological Chemistry, Volume 275, number 24, June 16, 2000, pages 17974-17978.	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		


Examiner Signature	M. Maruch	Date Considered	8/5/04
--------------------	-----------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

H:\doctid\usf-t144x.sids.doc\DNB\srp



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/049,502
Filing Date	February 13, 2002
First Named Inventor	Said M. Sebti
Art Unit	1633
Examiner Name	Maria B. Marvich, Ph.D.
Attorney Docket Number	USF-T144X

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
MM	U1	US-2004-0171547 A1	09-02-2004	Sebti	All
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner
Signature

M Marvich

Date
Considered

3/15/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/049,502
				Filing Date	February 13, 2002
				First Named Inventor	Said M. Sebt
				Group Art Unit	1633
				Examiner Name	Maria B. Marvich, Ph.D.
Sheet	2	of	3	Attorney Docket Number	USF-T144X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MM	R1	ADAMSON, P. <i>et al.</i> "Post-translational modifications of p21 ^{ras} proteins" <i>J Biol Chem</i> , 1992, 267:20033-20038.	
	R2	ADNANE, J. <i>et al.</i> "RhoB, not RhoA, represses the transcription of the transforming growth factor β type II receptor by a mechanism involving activator protein 1" <i>J Biol Chem</i> , 2002, 277:8500-8507.	
	R3	ARMSTRONG, S.A. <i>et al.</i> "CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB" <i>J Biol Chem</i> , 1995, 270:7864-7868.	
	R4	BARON, R. <i>et al.</i> "RhoB prenylation is driven by the three carboxyterminal amino acids of the protein: Evidenced <i>in vivo</i> by an anti-farnesyl cysteine antibody" <i>Proc Natl Acad Sci USA</i> , 2000, 97:11626-11631.	
	R5	CHANG, F. <i>et al.</i> "Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention" <i>Leukemia</i> , 2003, 17:1263-1293.	
	R6	CHARDIN, P. <i>et al.</i> "Coding sequence of human <i>rho</i> cDNAs clone 6 and clone 9" <i>Nucleic Acids Res.</i> 1988, 16: 2717.	
	R7	CLARK, E.A. <i>et al.</i> "Genomic analysis of metastasis reveals an essential role for RhoC" <i>Nature</i> , 2000, 406:532-535.	
	R8	DOWNWARD, J. "Targeting Ras signaling pathways in cancer therapy" <i>Nat Rev Cancer</i> , 2003, 3:11-22.	
	R9	FORGET, M.A. <i>et al.</i> "The expression of Rho proteins decreases with human brain tumor progression: potential tumor markers" <i>Clin Exp Metastasis</i> , 2002, 19(1):9-15.	
	R10	FRITZ, G. and KAINA, B. "Ras-related GTPase RhoB represses NF- κ B signaling" <i>J Biol Chem</i> , 2001, 276:3115-3122.	
	R11	FUKATA, M. <i>et al.</i> "Roles of Rho-family GTPases in cell polarisation and directional migration" <i>Curr Opin Cell Biol</i> , 2003, 15:590-597.	
	R12	GENBANK accession number X06820, "H. sapiens rhoB gene mRNA" October 24, 1996.	
MM	R13	GENBANK accession number CAA29968, "rhoB [Homo sapiens]" October 24, 1996.	

Examiner Signature	<i>M. Marvich</i>	Date Considered	3/15/06
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/049,502		
		Filing Date	February 13, 2002		
		First Named Inventor	Said M. Sebti		
		Group Art Unit	1633		
		Examiner Name	Maria B. Marvich, Ph.D.		
Sheet	3	of	3	Attorney Docket Number	USF-T144X

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mm	R14	JIANG, K. <i>et al.</i> "Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis" <i>Mol Cell Biol</i> , 2004, 24:5565-5576.	
mm	R15	JIANG, K. <i>et al.</i> "EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation" <i>Oncogene</i> , 2004, 23:1136-1145.	
dup mm	R16	LEBOWITZ, P.F. <i>et al.</i> "Phenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription" <i>J Biol Chem</i> , 1997, 272:16093-16095.	
mm	R17	LIU, A-X. <i>et al.</i> "RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells" <i>Mol Cell Biol</i> , 2001, 21:6906-6912.	
mm	R18	MAZIERES, J. <i>et al.</i> "Loss of RhoB expression in human lung cancer progression" <i>Clin Cancer Res</i> , 2004, 10:2742-2750.	
mm	R19	NAKAMURA, T. <i>et al.</i> "Cloning of the RhoB gene from the mouse genome and characterization of its promoter region" <i>Biochem. Biophys. Res. Commun.</i> , 1996, 226(3):688-694.	
mm	R20	NOBES, C.D. and HALL, A. "Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia" <i>Cell</i> , 1995, 81:53-62.	
mm	R21	SYMONS, M. and RUSK, N. "Control of vesicular trafficking by Rho GTPases" <i>Curr Biol</i> , 2003, 13:R409-418.	
mm	R22	WANG, D-A and SEBTI, S.M. "Palmitoylated cysteine 192 is required for RhoB tumor suppressive and apoptotic activities" Presentation at the American Association for Cancer Research, Anaheim, CA, April 16-20, 2005, abstract.	
mm	R23	WANG, D-A. and SEBTI, S.M. "Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities" <i>J. Biol. Chem.</i> , 2005, 280:19243-19249.	
mm	R24	WELSH, C.F. "Rho GTPases as key transducers of proliferative signals in G ₁ cell cycle regulation" <i>Breast Cancer Res Treat</i> , 2004, 84:33-42.	
	R		
	R		

Examiner Signature	<i>M. Marvich</i>	Date Considered	3/15/06
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/049,502
				Filing Date	February 13, 2002
				First Named Inventor	Said M. Sebti
				Art Unit	1633
				Examiner Name	Maria B. Marvich
Sheet	1	of	5	Attorney Docket Number	USF-T144X

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MM	U1	US-2002-0034725 A1	03-21-2002	McKenna et al.	All
MM	U2	US-11/274,368	11-14-2005	Sebti (patent application)	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code 2	- Number 4 - Kind Code 3 (if known)			
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature	M. Marvich	Date Considered	3/15/06
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/049,502		
		Filing Date	February 13, 2002		
		First Named Inventor	Said M. Sebti		
		Group Art Unit	1633		
		Examiner Name	Maria B. Marvich		
Sheet	2	of	5	Attorney Docket Number	USF-T144X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mm	R1	ADNANE, J. <i>et al.</i> "Suppression of Rho B expression in invasive carcinoma from head and neck cancer patients" <i>Clin Cancer Res</i> , 2002, 8:2225-2232.	
	R2	ALIMANDI, M. <i>et al.</i> "Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas" <i>Oncogene</i> , 1995, 10:1813-1821.	
	R3	ARBOLEDA, M.J. <i>et al.</i> "Overexpression of AKT2/protein kinase B β leads to up-regulation of β 1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells" <i>Cancer Res</i> , 2003, 63:196-206.	
	R4	BUDAY, L. and DOWNWARD, J. "Epidermal growth factor regulates p21 ^{ras} through the formation of a complex of receptor, Grb2 adaptor protein, and Sos nucleotide exchange factor" <i>Cell</i> , 1993, 73:611-620.	
	R5	DAVIES, M.A. <i>et al.</i> "Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells" <i>Clin Cancer Res</i> , 2002, 8:1904-1914.	
	R6	DU, W. and PRENDERGAST, G.C. "Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors" <i>Cancer Res</i> , 1999, 59:5492-5496.	
	R7	FORGET, M.A. <i>et al.</i> "The expression of Rho proteins decreases with human brain tumor progression: potential tumor markers" <i>Clin Exp Metastasis</i> , 2002, 19(1):9-15, abstract.	
	R8	FRITZ, G. and KAINA, B. "rhoB encoding a UV-inducible Ras-related small GTP-binding protein is regulated by GTPases of the Rho family and independent of JNK, ERK, and p38 MAP kinase" <i>J Biol Chem</i> , 1997, 272(49):30637-30644.	
	R9	FRITZ, G. <i>et al.</i> "The Ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments" <i>J Biol Chem</i> , 1995, 270(42):25172-25177.	
	R10	HALL, A. "Rho GTPases and the actin cytoskeleton" <i>Science</i> , 1998, 279(5350):509-514.	
	R11	HUNTER, T. "Oncoprotein networks" <i>Cell</i> , 1997, 88:333-346.	
	R12	JIANG, K. <i>et al.</i> "Regulation of Akt-dependent cell survival by Syk and Rac" <i>Blood</i> , 2003, 101:236-244.	
mm	R13	KHOSRAVI-FAR, R. and DER, C.J. "The Ras signal transduction pathway" <i>Cancer Metastasis Rev</i> , 1994, 13:67-89.	


Examiner Signature	<i>M. Marvich</i>	Date Considered	3/15/06
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/049,502		
		Filing Date	February 13, 2002		
		First Named Inventor	Said M. Sebti		
		Group Art Unit	1633		
		Examiner Name	Maria B. Marvich		
Sheet	3	of	5	Attorney Docket Number	USF-T144X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mm	R14	KIM, D. <i>et al.</i> "Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production" <i>Faseb J</i> , 2001, 15:1953-1962.	
	R15	KUBIATOWSKI, T. <i>et al.</i> "Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas" <i>J Neurosurg</i> , 2001, 95:480-488.	
	R16	LEBOWITZ, P.F. <i>et al.</i> "Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity" <i>Mol Cell Biol</i> , 1995, 15(12):6613-6622.	
	R17	LIU, A. <i>et al.</i> "RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors" <i>Mol Cell Biol</i> , 2000, 20(16):6105-6113.	
	R18	LIU, A. <i>et al.</i> "RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage" <i>Proc Natl Acad Sci USA</i> , 2001, 98(11):6192-6197.	
	R19	LUETTEKE, N.C. <i>et al.</i> "The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase" <i>Genes Dev</i> , 1994, 8:399-413.	
	R20	NAKAMURA, T. <i>et al.</i> "Cloning of the RhoB gene from the mouse genome and characterization of its promoter region" <i>Biochem. Biophys. Res. Commun.</i> , 1996, 226(3):688-694, abstract.	
	R21	PARK, B-K. <i>et al.</i> "Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells" <i>Cancer Res</i> , 2001, 61:7647-7653.	
	R22	PRUITT, K. and DER, C.J. "Ras and Rho regulation of the cell cycle and oncogenesis" <i>Cancer Lett.</i> , 2001, 171(1):1-10.	
	R23	QUILLIAM, L.A. <i>et al.</i> "Identification of residues critical for Ras(17N) growth-inhibitory phenotype and for Ras interaction with guanine nucleotide exchange factors" <i>Mol Cell Biol</i> , 1994, 14(2):1113-1121.	
	R24	STEWART, A.L. <i>et al.</i> "PI3K blockade by Ad-PTEN inhibits invasion and induces apoptosis in radial growth phase and metastatic melanoma cells" <i>Mol Med</i> , 2002, 8(8):451-461.	
	R25	SYMONS, M. and SETTLEMAN, J. "Rho family GTPases: more than simple switches" <i>Trends Cell Biol</i> , 2000, 10(10):415-419.	
mm	R26	TURKSON, J. <i>et al.</i> "Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein" <i>Mol Cell Biol</i> , 1999, 19(11):7519-7528.	

Examiner Signature	<i>M. Marvich</i>	Date Considered	3/15/06
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/049,502		
		Filing Date	February 13, 2002		
		First Named Inventor	Said M. Sebti		
		Group Art Unit	1633		
		Examiner Name	Maria B. Marvich		
Sheet	4	of	5	Attorney Docket Number	USF-T144X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MM	R27	VAN AELST, L. and D'SOUZA-SCHOREY, C. "Rho GTPases and signaling networks" <i>Genes Dev</i> , 1997, 11(18):2295-2322.	
	R28	VLAHOS, C.J. <i>et al.</i> "A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)" <i>J Biol Chem</i> , 1994, 269(7):5241-5248.	
	R29	YANO, H. <i>et al.</i> "Biochemical and pharmacological studies with KT7692 and LY294002 on the role of phosphatidylinositol 3-kinase in FcεRI-mediated signal transduction" <i>Biochem J</i> , 1995, 312(Pt 1):145-150.	
	R30	PENDERGAST and RANE "Farnesyltransferase inhibitors: mechanism and applications" <i>Expert Opin Invest Drugs</i> , 2001, 10(12):2105-2116.	
	R31	ADJEI, A.A. "Ras signaling pathway proteins as therapeutic targets" <i>Curr Pharm Design</i> , 2001, 7:1581-1594.	
	R32	CAPONIGRO, F. "Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy?" <i>Anti-Cancer Drugs</i> , 2002, 13:891-897.	
	R33	END, D.W. <i>et al.</i> "Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 <i>in vivo</i> and <i>in vitro</i> " <i>Cancer Res.</i> , 2001, 61:131-137.	
	R34	GURA, T. "Systems for identifying new drugs are often faulty" <i>Science</i> , 1997, 278:1041-1042.	
	R35	KERBEL, R.S. "Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans" <i>Cancer Biol. & Ther.</i> , 2003, 2(4 Supp. 1):S134-S139.	
	R36	REUTER, C.W. <i>et al.</i> "Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?" <i>Blood</i> , 2000, 96:1655-1669.	
	R37	ROBSON, T. and HIRST, D. "Transcriptional targeting in cancer gene therapy" <i>J. Biomed. Biotech.</i> , 2003, 2:110-137.	
	R38	SHI, B. <i>et al.</i> "The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes <i>in vitro</i> and enhances their antitumor activity <i>in vivo</i> " <i>Cancer. Chemother. Pharmacol.</i> , 2000, 46:387-393.	
MM	R39	VOSKOGLOU-NOMIKOS, T. <i>et al.</i> "Clinical predictive value of the <i>in vitro</i> cell line, human xenograft, and mouse allograft preclinical cancer models" <i>Clin. Cancer Res.</i> , 2003, 9:4227-4239.	


Examiner Signature	M Marvich	Date Considered	3/15/06
--------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/049,502		
		Filing Date	February 13, 2002		
		First Named Inventor	Said M. Sebti		
		Group Art Unit	1633		
		Examiner Name	Maria B. Marvich		
Sheet	5	of	5	Attorney Docket Number	USF-T144X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mm	R40	SUN, J. et al. "Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine" <i>Cancer Res.</i> , 1999, 59:4919-4926.	
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		

Examiner Signature	M. Marvich	Date Considered	3/15/06
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.